BioSpace News Archive

Bristol Myers Squibb announced four-year follow-up results from the Phase 3 CheckMate -9LA trial demonstrating durable, long-term survival benefits with Opdivo plus Yervoy with two cycles of chemotherapy compared to four cycles of chemotherapy alone in previously untreated patients with metastatic non-small cell lung cancer.

Day One Biopharmaceuticals announced new data from the registrational Phase 2 FIREFLY-1 trial evaluating the investigational agent tovorafenib.

This was a Phase 2, double-masked, randomized, vehicle-controlled, dose-response study to assess the safety and ocular hypotensive efficacy of VVN539 in subjects with primary open angle glaucoma or ocular hypertension.

LOTTE BIOLOGICS, under the leadership of CEO Richard Lee, enthusiastically disclosed its participation in the upcoming ‘BIO International Convention 2023' to be held from June 5th to June 8th, 2023, at the illustrious Boston Convention & Exhibition Center, USA.

VITRAC Therapeutics, LLC presented a poster on the Phase 1a/1b clinical trial of aurora kinase A inhibitor, VIC-1911, as monotherapy and in combination with KRAS G12C inhibitor, sotorasib.

Chimeric Therapeutics is pleased to announce activation of a Phase 1B clinical trial in patients with recurrent and/ or progressive glioblastoma multiforme to assess the safety and efficacy of CHM 1101, the company’s first in class CLTX CAR T cell therapy.

Harbour BioMed announced that the first patient has been dosed in its ongoing phase I trial of the first-in-class anti-B7H7 antibody HBM1020 in the United States.

G1 Therapeutics, Inc., a commercial-stage oncology company, presented results from 24 patients enrolled in its Phase 2, single arm mechanism of action study of trilaciclib administered as a single agent to patients with early-stage triple-negative breast cancer prior to receiving trilaciclib and neoadjuvant therapy.

Amgen announced the presentation of new data from the CodeBreaK clinical trial program, the most comprehensive global development program in patients with KRAS G12C-mutated cancers, at the American Society of Clinical Oncology Annual Meeting taking place June 2-6 in Chicago.

Positive results from the ADAURA Phase III trial showed AstraZeneca’s TAGRISSO® demonstrated a statistically significant and clinically meaningful improvement in overall survival, compared to placebo in the adjuvant treatment of patients with early-stage epidermal growth factor receptor-mutated non-small cell lung cancer after complete tumor resection with curative intent.